Latest news

• Takeda’s dengue vaccine seems safe with no prior virus exposure

  Appears unaffected by serious safety issue affecting Sanofi rival. Takeda says new data shows its candidate vaccine for dengue fever TAK-003 is effective, and crucially doesn’t seem to be ... It’s also investing in production capacity for TAK-003,

• Sanofi confirms suspected safety issue with dengue vaccine

  The setbacks for Dengvaxia provide an opportunity for rival Takeda to leapfrog Sanofi with its own dengue vaccine candidate TAK-003, which has showed a higher rate of protective efficacy in ... Industry watchers have suggested TAK-003 could be on the

• Takeda dengue vaccine data looks good as it chases Sanofi

  TAK-003 achieved a 71% reduction in developing the virus compared to placebo. ... The reduced incidence of dengue in children and adolescents receiving TAK-003 is encouraging, however data from our ongoing Phase 3 efficacy trial, TIDES, are required to

• Takeda plans German plant to support dengue vaccine roll-out

  The plant in Singen is a "major step towards meeting important unmet needs in dengue prevention," according to the Japanese drugmaker, which recently started a phase III trial of its ... Takeda started its phase III TIDES trial of the live-attenuated